• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用PTEN缺陷型三阴性乳腺癌细胞系的染色体不稳定性以复制依赖的方式增强对PARP1抑制的敏感性。

Exploiting Chromosomal Instability of PTEN-Deficient Triple-Negative Breast Cancer Cell Lines for the Sensitization against PARP1 Inhibition in a Replication-Dependent Manner.

作者信息

Rieckhoff Johanna, Meyer Felix, Classen Sandra, Zielinski Alexandra, Riepen Britta, Wikman Harriet, Petersen Cordula, Rothkamm Kai, Borgmann Kerstin, Parplys Ann Christin

机构信息

Laboratory of Radiobiology & Experimental Radio Oncology, Centre of Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Department of Tumor Biology, Center of Experimental Medicine, University Medical Center, Hamburg-Eppendorf, 20246 Hamburg, Germany.

出版信息

Cancers (Basel). 2020 Sep 29;12(10):2809. doi: 10.3390/cancers12102809.

DOI:10.3390/cancers12102809
PMID:33003585
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7601067/
Abstract

Chromosomal instability (CIN) is an emerging hallmark of cancer and its role in therapeutic responses has been increasingly attracting the attention of the research community. To target the vulnerability of tumors with high CIN, it is important to identify the genes and mechanisms involved in the maintenance of CIN. In our work, we recognize the tumor suppressor gene Phosphatase and Tensin homolog ( as a potential gene causing CIN in triple-negative breast cancer (TNBC) and show that TNBC with low expression levels of PTEN can be sensitized for the treatment with poly-(ADP-ribose)-polymerase 1 (PARP1) inhibitors, independent of Breast Cancer (BRCA) mutations or a BRCA-like phenotype. In silico analysis of mRNA expression data from 200 TNBC patients revealed low expression of PTEN in tumors with a high CIN70 score. Western blot analysis of TNBC cell lines confirm lower protein expression of PTEN compared to non TNBC cell lines. Further, PTEN-deficient cell lines showed cellular sensitivity towards PARP1 inhibition treatment. DNA fiber assays and examination of chromatin bound protein fractions indicate a protective role of PTEN at stalled replication forks. In this study, we recognize as a potential CIN-causing gene in TNBC and identify its important role in the replication processes.

摘要

染色体不稳定(CIN)是癌症新出现的一个特征,其在治疗反应中的作用越来越受到研究界的关注。为了针对具有高CIN的肿瘤的脆弱性,识别参与维持CIN的基因和机制很重要。在我们的研究中,我们认识到肿瘤抑制基因磷酸酶和张力蛋白同源物(PTEN)是三阴性乳腺癌(TNBC)中导致CIN的一个潜在基因,并表明PTEN低表达水平的TNBC对聚(ADP - 核糖)聚合酶1(PARP1)抑制剂治疗敏感,这与乳腺癌(BRCA)突变或BRCA样表型无关。对200例TNBC患者的mRNA表达数据进行的计算机分析显示,在CIN70评分高的肿瘤中PTEN表达较低。对TNBC细胞系的蛋白质免疫印迹分析证实,与非TNBC细胞系相比,PTEN的蛋白质表达更低。此外,PTEN缺陷的细胞系对PARP1抑制治疗表现出细胞敏感性。DNA纤维分析和对染色质结合蛋白组分的检测表明PTEN在停滞的复制叉处具有保护作用。在本研究中,我们认识到PTEN是TNBC中一个潜在的导致CIN的基因,并确定了其在复制过程中的重要作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7976/7601067/80fddbdd4109/cancers-12-02809-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7976/7601067/5992d400b496/cancers-12-02809-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7976/7601067/4f853b36c906/cancers-12-02809-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7976/7601067/1a7dbe76ce2d/cancers-12-02809-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7976/7601067/80fddbdd4109/cancers-12-02809-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7976/7601067/5992d400b496/cancers-12-02809-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7976/7601067/4f853b36c906/cancers-12-02809-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7976/7601067/1a7dbe76ce2d/cancers-12-02809-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7976/7601067/80fddbdd4109/cancers-12-02809-g005.jpg

相似文献

1
Exploiting Chromosomal Instability of PTEN-Deficient Triple-Negative Breast Cancer Cell Lines for the Sensitization against PARP1 Inhibition in a Replication-Dependent Manner.利用PTEN缺陷型三阴性乳腺癌细胞系的染色体不稳定性以复制依赖的方式增强对PARP1抑制的敏感性。
Cancers (Basel). 2020 Sep 29;12(10):2809. doi: 10.3390/cancers12102809.
2
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.组蛋白去乙酰化酶抑制剂,辛二酰苯胺异羟肟酸(SAHA),增强了聚(ADP - 核糖)聚合酶(PARP)抑制剂奥拉帕尼在三阴性乳腺癌细胞中的抗肿瘤作用。
Breast Cancer Res. 2015 Mar 7;17:33. doi: 10.1186/s13058-015-0534-y.
3
Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.应用新一代测序技术重新定义三阴性乳腺癌的 BRCA 状态。
Cancer Sci. 2020 Apr;111(4):1375-1384. doi: 10.1111/cas.14313. Epub 2020 Feb 19.
4
The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.癌蛋白 DEK 影响轻度复制应激期间 PARP1/2 抑制的结果。
PLoS One. 2019 Aug 13;14(8):e0213130. doi: 10.1371/journal.pone.0213130. eCollection 2019.
5
Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.三阴性乳腺癌中聚(ADP-核糖)聚合酶(PARP)和组蛋白去乙酰化酶(HDAC)的联合靶向治疗:BRCA 突变细胞中更高的协同作用。
Biomed Pharmacother. 2018 Mar;99:543-551. doi: 10.1016/j.biopha.2018.01.045. Epub 2018 Feb 20.
6
MicroRNA-498 promotes proliferation and migration by targeting the tumor suppressor PTEN in breast cancer cells.微小 RNA-498 通过靶向乳腺癌细胞中的肿瘤抑制因子 PTEN 促进增殖和迁移。
Carcinogenesis. 2018 Sep 21;39(9):1185-1196. doi: 10.1093/carcin/bgy092.
7
Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer.三阴性乳腺癌全球基因表达谱的荟萃分析确定了用于预测和治疗侵袭性乳腺癌的基因。
Oncogenesis. 2014 Apr 21;3(4):e100. doi: 10.1038/oncsis.2014.14.
8
The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.雄激素受体阳性三阴性乳腺癌中PARP1与BRCA1的相关性
Int J Biol Sci. 2016 Nov 25;12(12):1500-1510. doi: 10.7150/ijbs.16176. eCollection 2016.
9
Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.三阴性乳腺癌及其他原发性人类肿瘤类型中聚(ADP-核糖)聚合酶-1(PARP1)的上调
Genes Cancer. 2010 Aug;1(8):812-21. doi: 10.1177/1947601910383418.
10
Treatment of PTEN-Null Breast Cancer by a Synthetic Lethal Approach Involving PARP1 Gene Silencing.通过 PARP1 基因沉默的合成致死方法治疗 PTEN 缺失型乳腺癌。
J Pharm Sci. 2023 Jul;112(7):1908-1914. doi: 10.1016/j.xphs.2023.02.017. Epub 2023 Feb 23.

引用本文的文献

1
Re-epithelialization of cancer cells increases autophagy and DNA damage: Implications for breast cancer dormancy and relapse.癌细胞的再上皮化增加自噬和DNA损伤:对乳腺癌休眠和复发的影响。
Sci Signal. 2025 Apr 22;18(883):eado3473. doi: 10.1126/scisignal.ado3473.
2
Targeting FEN1/EXO1 to enhance efficacy of PARP inhibition in triple-negative breast cancer.靶向FEN1/EXO1以增强聚(ADP-核糖)聚合酶抑制在三阴性乳腺癌中的疗效。
Transl Oncol. 2025 Apr;54:102337. doi: 10.1016/j.tranon.2025.102337. Epub 2025 Mar 6.
3
Micro-RNAs in breast cancer progression and metastasis: A chromatin and metabolic perspective.

本文引用的文献

1
Response to Olaparib in a Patient with Germline Mutation and Breast Cancer Leptomeningeal Carcinomatosis.胚系突变型乳腺癌软脑膜癌病患者对奥拉帕尼的反应
NPJ Breast Cancer. 2019 Nov 29;5:46. doi: 10.1038/s41523-019-0139-1. eCollection 2019.
2
Mild replication stress causes chromosome mis-segregation via premature centriole disengagement.轻度复制应激通过过早的中心体脱离导致染色体错误分离。
Nat Commun. 2019 Aug 8;10(1):3585. doi: 10.1038/s41467-019-11584-0.
3
Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.
从染色质和代谢角度看微小RNA在乳腺癌进展和转移中的作用
Heliyon. 2024 Sep 20;10(19):e38193. doi: 10.1016/j.heliyon.2024.e38193. eCollection 2024 Oct 15.
4
Chromosomal instability: a key driver in glioma pathogenesis and progression.染色体不稳定性:胶质母细胞瘤发病机制和进展的关键驱动因素。
Eur J Med Res. 2024 Sep 4;29(1):451. doi: 10.1186/s40001-024-02043-8.
5
Chromosomal Instability as Enabling Feature and Central Hallmark of Breast Cancer.染色体不稳定作为乳腺癌的促成特征和核心标志
Breast Cancer (Dove Med Press). 2023 Mar 9;15:189-211. doi: 10.2147/BCTT.S383759. eCollection 2023.
6
The progress in our understanding of CIN in breast cancer research.我们对乳腺癌研究中导管原位癌(CIN)认识的进展。
Front Oncol. 2023 Feb 16;13:1067735. doi: 10.3389/fonc.2023.1067735. eCollection 2023.
7
Up to your NEK2 in CIN.在染色体不稳定性方面取决于你的NEK2。
Oncotarget. 2021 Apr 13;12(8):723-725. doi: 10.18632/oncotarget.27918.
8
DNA Damage Response during Replication Correlates with CIN70 Score and Determines Survival in HNSCC Patients.复制过程中的DNA损伤反应与CIN70评分相关,并决定头颈部鳞状细胞癌患者的生存情况。
Cancers (Basel). 2021 Mar 10;13(6):1194. doi: 10.3390/cancers13061194.
苯丁酸氮芥靶向 BRCA1/2 缺陷型肿瘤并克服 PARP 抑制剂耐药性。
EMBO Mol Med. 2019 Jul;11(7):e9982. doi: 10.15252/emmm.201809982. Epub 2019 May 24.
4
The emerging links between chromosomal instability (CIN), metastasis, inflammation and tumour immunity.染色体不稳定性(CIN)、转移、炎症与肿瘤免疫之间新出现的联系。
Mol Cytogenet. 2019 May 14;12:17. doi: 10.1186/s13039-019-0429-1. eCollection 2019.
5
Advances in understanding DNA processing and protection at stalled replication forks.在停滞复制叉处理解 DNA 加工和保护的进展。
J Cell Biol. 2019 Apr 1;218(4):1096-1107. doi: 10.1083/jcb.201809012. Epub 2019 Jan 22.
6
Mechanisms for stalled replication fork stabilization: new targets for synthetic lethality strategies in cancer treatments.停滞复制叉稳定的机制:癌症治疗中合成致死策略的新靶点。
EMBO Rep. 2018 Sep;19(9). doi: 10.15252/embr.201846263. Epub 2018 Aug 13.
7
Targeting ATR in cancer.在癌症中靶向 ATR。
Nat Rev Cancer. 2018 Sep;18(9):586-595. doi: 10.1038/s41568-018-0034-3.
8
Loss of PTEN in high grade advanced stage triple negative breast ductal cancers in African American women.非洲裔美国女性高级别晚期三阴性乳腺导管癌中PTEN的缺失。
Pathol Res Pract. 2018 May;214(5):673-678. doi: 10.1016/j.prp.2018.03.020. Epub 2018 Mar 27.
9
Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer.PTEN 辅助的 G2/M 检查点丧失会阻碍同源重组修复,并增强前列腺癌的放射治疗敏感性和 PARP 抑制剂治疗反应。
Sci Rep. 2018 Mar 2;8(1):3947. doi: 10.1038/s41598-018-22289-7.
10
PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation.PARP1和PARP2通过Fbh1依赖的Rad51调控,在碱基切除修复中间体处稳定复制叉。
Nat Commun. 2018 Feb 21;9(1):746. doi: 10.1038/s41467-018-03159-2.